[CAS NO. 179411-94-0] SDZ220-581Ammoniumsalt
PRODUCTS SPECIFICATIONS [179411-94-0]
DESCRIPTION [179411-94-0]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 386.77 |
| Molecular Formula | C16H20ClN2O5P |
| SMILES | ClC1=CC=CC=C1C2=CC(C[C@H](N)C(O)=O)=CC(CP(O)(O)=O)=C2.N |
Summary
SDZ 220-581 Ammonium salt is an orally active, potent, competitive NMDA receptor antagonist with pK i value of 7.7 [1] .
IC50 & Target
pKi: 7.7 ( NMDA receptor ) [1]
In Vivo
SDZ 220-581 (3.2-32 mg/kg; oral administration; for 24 hours; male OF-l mice) treatment dose-dependently protects mice against maximal electroshock seizures (MES). The time-course of protection by SDZ 220-581 is characterized by a rapid onset and long duration of action [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Male OF-l mice (18-26 g) [1] |
| Dosage: | 3.2 mg/kg, 10 mg/kg, 32 mg/kg |
| Administration: | Oral administration; for 24 hours |
| Result: | Dose-dependently protected mice against maximal electroshock seizures (MES) upon oral administration. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
References
- [1] Urwyler S, et al. Biphenyl-derivatives of 2-amino-7-phosphono-heptanoic acid, a novel class of potent competitive N-methyl-D-aspartate receptor antagonists--II. Pharmacological characterization in vivo. Neuropharmacology. 1996 Jun;35(6):655-69.
- [2] Gilmour G, et al. In vitro characterisation of the novel positive allosteric modulators of the mGlu₅ receptor, LSN2463359 and LSN2814617, and their effects on sleep architecture and operant responding in the rat. Neuropharmacology. 2013 Jan;64:224-39.
